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Introduction: Acute kidney injury (AKI) risk prediction scores are an objective and transparent means to enable
cohort enrichment in clinical trials or to risk stratify patients preoperatively. Existing scores are limited in that they
have been designed to predict only severe, or non-consensus AKI definitions and not less severe stages of AKI,
which also have prognostic significance. The aim of this study was to develop and validate novel risk scores that
could identify all patients at risk of AKI.
Methods: Prospective routinely collected clinical data (n = 30,854) were obtained from 3 UK cardiac surgical centres
(Bristol, Birmingham and Wolverhampton). AKI was defined as per the Kidney Disease: Improving Global Outcomes
(KDIGO) Guidelines. The model was developed using the Bristol and Birmingham datasets, and externally validated
using the Wolverhampton data. Model discrimination was estimated using the area under the ROC curve (AUC).
Model calibration was assessed using the Hosmer–Lemeshow test and calibration plots. Diagnostic utility was also
compared to existing scores.
Results: The risk prediction score for any stage AKI (AUC = 0.74 (95% confidence intervals (CI) 0.72, 0.76)) demonstrated
better discrimination compared to the Euroscore and the Cleveland Clinic Score, and equivalent discrimination to the
Mehta and Ng scores. The any stage AKI score demonstrated better calibration than the four comparison scores. A
stage 3 AKI risk prediction score also demonstrated good discrimination (AUC = 0.78 (95% CI 0.75, 0.80)) as did the four
comparison risk scores, but stage 3 AKI scores were less well calibrated.
Conclusions: This is the first risk score that accurately identifies patients at risk of any stage AKI. This score will be
useful in the perioperative management of high risk patients as well as in clinical trial design.Introduction
Acute kidney injury (AKI) is a common and severe
complication of cardiac surgery affecting up to 30% of
all patients and increasing mortality up to fourfold
[1,2]. No effective treatment has been identified despite
over 70 randomised controlled trials (RCTs) of proposed
renoprotective interventions [3,4]. Systematic reviews have
documented important limitations in these trials such as
the enrolment of low or mixed AKI-risk patient cohorts,
small sample sizes, and low statistical power [3,4].* Correspondence: gjm19@le.ac.uk
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unless otherwise stated.These are important sources of bias that will have
increased the likelihood of negative trial results. Recent
recommendations on the design of trials in AKI suggest
that these limitations may be countered by cohort
enrichment [5], whereby the enrolment of patients with
higher event rates will permit targeting of interventions to
those patients populations most likely to benefit,
smaller sample sizes, and increased study power. AKI
risk prediction scores are an objective, transparent
means of cohort enrichment but are not widely used.
This is because existing scores have been developed
principally to identify patients at risk of renal replacement
therapy (RRT) which is rare and not less severe AKI,
which is also associated with poor prognosis but occurs
with greater frequency [6]. There is also uncertainty as totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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scores, The Cleveland clinic score [7], and the Mehta
score [8] have been independently validated, and neither
has demonstrated adequate discrimination and calibration
in non-North American patient populations [9,10].
The aim of this study was to develop and externally
validate two novel risk scores that could be used for
cohort enrichment in clinical trials of renoprotective
interventions in cardiac surgery. We used the Kidney
Disease: Improving Global Outcomes (KDIGO) guidelines
AKI definition [11] as this reconciles important differences
between the two earlier consensus definitions; Acute
Kidney Injury Network (AKIN) [12] and risk, injury,
failure, loss, end stage (RIFLE) [13]. The prognostic
utility of this score has only been demonstrated thus
far in a single centre [14]. To support the validity
and utility of the risk scores our first objective was
therefore to demonstrate the utility of the KDIGO
definition in a large multicentre cohort. Next, we developed
two new scores based on preoperative variables; one to
identify all patients at risk of AKI (KDIGO stages 1 to 3),
and the second to identify only those patients at risk
of severe AKI (KDIGO stage 3). Finally we compared
the diagnostic utility of these new scores with four
published risk scores.
Methods
This study was approved by the South West research
ethics committee under reference 11/SW/0075. The
requirement for written informed consent was waived.
Our research objectives and methods were specified
prior to execution.
Study population
This retrospective cohort study used routinely collected
data from the patient analysis and tracking system (PATS),
from three UK hospitals. We obtained prospectively
collected data on all adult cardiac patients for the following
periods: 1996 to 2010 at University Hospitals of Bristol,
2002 to 2010 at University Hospitals of Birmingham
National Health Service (NHS) Foundation Trust, and
2004 to 2010 at Wolverhampton Heart and Lung Centre.
Our analyses included all patients aged ≥16 years, who
underwent cardiac surgery, with or without cardiopulmo-
nary bypass (CBP), and including those who underwent
surgery to the thoracic aorta; we excluded patients already
on renal replacement therapy (RRT) or who had received a
kidney transplants, and patients who died in theatre.
Definitions of perioperative variables used were consist-
ent across the three sites, and are as specified by the UK
National Adult Cardiac Surgery Audit (NACSA) [15].
NACSA is a component of the UK cardiac surgery national
quality assurance programme, whereby a defined set
of perioperative data are collected prospectively bythe anaesthetist, surgeon, and ICU, high-dependency
unit (HDU), and ward nurses on the PATS databases.
These data are submitted to the National Institute
Clinical Outcome Research (NICOR) for analysis and
the generation of risk-adjusted outcome data [16].
The data undergo routine internal quality assurance
prior to submission as well as external data quality
assessment by NICOR. The NACSA Annual Report
for 2010 indicated that these three centres are among
the best units nationally for data quality [17]. PATS
data were linked using name, hospital number, and
date of birth, to institutional biochemistry databases
that record serial serum creatinine results, to identify
those patients who developed AKI. During the study
serum creatinine was measured using the Jaffe method at
all three centres. Wolverhampton and Birmingham used
the Roche Modular system (Roche Diagnostics, Ltd, Lewes,
UK). Bristol used the Olympus Diagnostics System AU640
or AU2700 (Olympus Diagnostic Systems, Southall, UK).
The assays were calibrated using the manufacturers’ con-
trols with inter-institutional diagnostic accuracy monitored
by a national (UK) quality assessment scheme.
Definitions
Measurement of acute kidney injury
AKI was classified according to the KDIGO guidelines
[11]. Stage-1 AKI was defined as an increase from
baseline of ≥26 μmol/L of postoperative creatinine or
an increase of 1.5 to 1.9 times the preoperative creatinine
within 7 days; stage 2 was an increase of 2.0 to 2.9
times the preoperative creatinine; stage-3 AKI was an
increase ≥3 times the preoperative creatinine or an
increase to ≥354 μmol/L or when the patient commenced
RRT. The RRT was administered for uraemia, volume
overload, or biochemical abnormalities, according to
institutional protocols. Urine output data were not
available and therefore not used in our AKI definition. The
baseline creatinine value was defined as the preoperative
value obtained closest to the date of the operation. Cases
where the baseline data were missing, most commonly
emergency and salvage patients, were not included in the
complete case analyses.
Demographic factors
Information was extracted from PATS on age (grouped into
three categories: <60; 60 to 74; or ≥75 years), sex, body
mass index (BMI) (grouped into five categories: <20.0; 20.0
to 24.9; 25.0 to 29.9; 30.0 to 34.9; or ≥35.0 kg/m2) and
smoking status (never smoked; ex-smoker; or current
smoker).
Preoperative factors
Information on prespecified factors was obtained from
PATS for the three centres. The presence of angina was
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(CCS) categories: no angina, CCS 1 (ordinary activity does
not cause angina); CCS 2 (slight limitation); CCS 3
(moderate limitation); or CCS 4 (inability to carry out
any physical activity without discomfort). Dyspnoea
was grouped according to the New York Heart Association
(NYHA) functional classification: NYHA 1 (no symptoms
and no limitation in ordinary physical activity); NHYA 2
(mild symptoms and slight limitation during ordinary
activity); NYHA 3 (marked limitation in activity due
to symptoms, comfortable only at rest); or NYHA 4
(severe limitations, experiences symptoms even while
at rest). Previous myocardial infarction (MI) was categorised
as; none; 1; or ≥2. Information was obtained on previous
cardiac, vascular or thoracic surgery (0 and ≥1), the
presence of diabetes, peripheral vascular disease, pulmonary
disease, neurological disease, hypertension (treated or blood
pressure (BP) >140/90) and preoperative haemoglobin
(<10.0; 10.0 to 11.9; or ≥12.0 g/dL). Glomerular filtration
rate (GFR) was estimated from the Cockcroft-Gault
equation using the preoperative creatinine value obtained
closest to the day of surgery, and grouped as: <30.0; 30.0
to 59.9; 60.0 to 89.9; or ≥90 μmol/L. Heparin or nitrates
usage was grouped according to: none; within a week; or
at operation. Any critical preoperative event was consid-
ered to be cardiogenic shock; preoperative intravenouse
(IV) inotropes; or preoperative ventilation or intra-aortic
balloon pump (IABP). The time between catheterisation
and surgery was grouped as: within 24 hours; >24 hours
for this admission; or >24 hours for a previous admission.
Information was obtained on triple vessel disease, left
main stem disease, ejection fraction (grouped as:
good ≥50%; fair 30 to 49%; or poor <30%), operative
priority (elective, urgent and emergency/salvage). Finally
the cardiac procedures being undertaken were classified
as coronary artery bypass graft surgery (CAGB) only; valve
only; or CABG and valve and other/multiple. Procedures
classed as other included major aortic surgery; left
ventricular aneurysmectomy; atrial myxoma surgery;
pulmonary embolectomy; epicardial pacemaker placement;
pericardectomy; atrial septal defect closure; proced-
ure for congenital conditions; acquired ventricular
septal defect closure; pulmonary endarterectomy;
atrial fibrillation ablation; myomectomy; cardiac sur-
gery plus carotid endarterectomy or peripheral vascular
procedures; or any other cardiothoracic procedure not
listed above.
Outcomes following surgery
Information on pulmonary complications (reintuba-
tion and ventilation; full tracheostomy; need for CPAP or
BIPAP; or prolonged ventilation >48 hours), infectious
complications (sternal wound infection; leg wound infec-
tion; chest infection; or septicaemia or other infection),length of stay in hospital (in days) and death in hospital
was obtained from PATS.
Statistical analyses
The association between AKI and outcomes following
surgery were modelled using logistic regression models.
The data from Bristol and Birmingham were used to
develop the prognostic models (development sample)
and the models were validated on the data from
Wolverhampton (validation sample). Any-stage AKI
and stage-3 AKI were modelled using separate logistic
regression models. Univariable associations were examined
for all demographic and preoperative factors. Mutivariable
associations were examined by entering all demographic
and preoperative factors into a single model, which
controlled for all these main effects, in a full model.
Factors selected for the initial prognostic model were
those from the multivariable full model with P <0.001.
Factors selected for the more inclusive prognostic model
were those from the full model with P <0.05. The area
under the receiver operating characteristic (ROC) curve
(AUC) was calculated for each model in the development
and validation samples to quantify diagnostic utility. Model
calibration was assessed using the Hosmer-Lemeshow test
and calibration plots. Calibration plots of observed versus
predicted values for AKI were analysed using linear
regression to provide the slope and intercept where
the closer the intercept to 0, and the closer the slope
to 1, the better the calibration. The discrimination
and calibration of the models were compared to two
published AKI risk scores from US data [7,8], a recently
published risk score from Australia [10] as well as a
mortality risk score - the logistic Euroscore [18]. We
were able to match all the variables for the Cleveland
clinic score [7] except congestive heart failure and left
ventricular ejection fraction <35% (data cut at <30%).
For the Ng score [10] we were able to match all the
variables with the exception of infective endocarditis.
For the Mehta score [8] we were unable to match
ethnicity in the development sample, and were unable
to precisely match the field MI within 3 weeks, or
the type of valve procedure (mitral versus aortic).
We conducted sensitivity analyses, first by considering
the inclusion of two-way interactions in our score,
and second, by using multiple imputations by chained
equations [19,20] to account for missing data. The
analysis assumes any systematic difference between the
missing values and the observed values can be explained
by differences in observed data. We used the ice command
[21] in Stata to impute confounder and outcome missing
data. Variables that may help explain the missing data
(for example, demographic information, preoperative
factors, AKI status and outcomes following surgery)
were included in the imputation model. The missing
Table 1 Number and percentage missing for each variable by centre
Bristol (n = 18,686) Birmingham (n = 7,306) Wovlerhampton (n = 4,862)
Variable Number % Number % Number %
Age 0 0.0 0 0.0 0 0.0
Sex 2 0.0 0 0.0 0 0.0
Body mass index 341 1.8 29 0.4 1 0.0
Smoking status 114 0.6 28 0.4 1 0.0
Angina 79 0.4 15 0.2 0 0.0
Dyspnoea 93 0.5 20 0.3 0 0.0
Previous MI 54 0.3 37 0.5 10 0.2
Previous operations 15 0.1 9 0.1 0 0.0
Preoperative diabetes 75 0.4 15 0.2 0 0.0
Peripheral vascular disease 67 0.4 16 0.2 0 0.0
Pulmonary disease 65 0.4 18 0.3 0 0.0
Neurological disease 59 0.3 14 0.2 0 0.0
Hypertension 130 0.7 29 0.4 1 0.0
Haemoglobin 1,298 7.0 2,846 39.0 28 0.6
Baseline serum creatinine 282 1.5 66 0.9 19 0.4
GFR 537 2.9 86 1.2 19 0.4
Heparin or nitrates 51 0.3 18 0.3 0 0.0
Critical preoperative event 0 0.0 12 0.2 0 0.0
Catheterisation to surgery 1,447 7.7 398 5.5 242 5.0
Triple vessel disease 938 5.0 252 3.5 85 1.8
Left main stem disease 2,286 12.2 245 3.4 83 1.7
Ejection fraction 493 2.6 86 1.2 0 0.0
Operative priority 23 0.1 0 0.0 0 0.0
Cardiac procedures 0 0.0 0 0.0 0 0.0
Postoperative creatinine 282 1.5 66 0.9 84 1.7
Acute kidney injury 629 3.4 215 2.9 84 1.7
Acute kidney injury stage 629 3.4 215 2.9 84 1.7
Postoperative stay 10 0.1 0 0.0 0 0.0
Infective complication 1,564 8.4 61 0.8 96 2.0
Pulmonary complication 1,651 8.8 53 0.7 100 2.1
Died in hospital 1 0.0 6 0.1 0 0.0
Euroscore 129 0.7 48 0.7 6 0.1
Cleveland clinic score* 731 3.9 139 1.9 19 0.4
Mehta score* 369 2.0 101 1.4 29 0.6
Ng score* 613 3.3 92 1.3 20 0.4
*Approximation to scores, matching where data are available. MI, myocardial infaction.
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tion, based on the observed data. Standard regression
analyses were used to fit the model of interest to
each of the imputed datasets. Ten cycles of regression
were carried out and 20 datasets imputed. All 20 esti-
mated associations were combined to give one overall
estimated association of interest. Standard error was
calculated using the Rubin rules [22,23]. These rulestook into account the variability in results between
the imputed datasets, indicating the uncertainty of
the missing values. All analyses were carried out in
StataTM version 13.
Online calculator
We constructed a web-based calculator for the any-stage
AKI risk score [24].
Table 2 Characteristics of patients by centre in the complete case data
Bristol (n = 12,435) Birmingham (n = 4,092) Wolverhampton (n = 4,468)
Number (%) Number (%) Number (%)
Demographic factors
Age, years
<60 2,995 (24.1) 1,061 (25.9) 1,026 (23.0)
60 to 74 6,873 (55.3) 2,201 (53.8) 2,471 (55.3)
≥75 2,567 (20.6) 830 (20.3) 971 (21.7)
Sex
Male 9,474 (76.2) 2,990 (73.1) 3,420 (76.5)
Female 2,961 (23.8) 1,102 (26.9) 1,048 (23.5)
Body mass index
<20.0 482 (3.9) 112 (2.7) 87 (1.9)
20.0 to 24.9 3,206 (25.8) 1,003 (24.5) 1,057 (23.7)
25.0 to 29.9 5,685 (45.7) 1,737 (42.4) 2,020 (45.2)
30.0 to 34.9 2,365 (19.0) 893 (21.8) 967 (21.6)
35.0+ 697 (5.6) 347 (8.5) 337 (7.5)
Smoking status
Never smoked 3,970 (31.9) 1,351 (33.0) 1,633 (36.5)
Ex-smoker 7,072 (56.9) 2,427 (59.3) 2,414 (54.0)
Current smoker 1,393 (11.2) 314 (7.7) 421 (9.4)
Preoperative factors
Anginaa
No angina 2,346 (18.9) 737 (18.0) 779 (17.4)
CCS 1 1,460 (11.7) 399 (9.8) 244 (5.5)
CCS 2 3,611 (29.0) 1,354 (33.1) 1,342 (30.0)
CCS 3 2,885 (23.2) 949 (23.2) 1,142 (25.6)
CCS 4 2,133 (17.2) 653 (16.0) 961 (21.5)
Dyspnoeab
NYHA 1 2,797 (22.5) 786 (19.2) 926 (20.7)
NHYA 2 5,129 (41.2) 2,094 (51.2) 1,748 (39.1)
NYHA 3 3,895 (31.3) 928 (22.7) 1,353 (30.3)
NYHA 4 614 (4.9) 284 (6.9) 441 (9.9)
Previous MI
0 7,786 (62.6) 2,671 (65.3) 2,453 (54.9)
1 3,783 (30.4) 1,145 (28.0) 1,620 (36.3)
≥2 866 (7.0) 276 (6.7) 395 (8.8)
Previous operations
0 1,1940 (96.0) 3,895 (95.2) 4,352 (97.4)
1+ 495 (4.0) 197 (4.8) 116 (2.6)
Preoperative diabetes
No 10,243 (82.4) 3,176 (77.6) 3,399 (76.1)
Yes 2,192 (17.6) 916 (22.4) 1,069 (23.9)
Peripheral vascular disease
No 11,388 (91.6) 3,536 (86.4) 3,665 (82.0)
Yes 1,047 (8.4) 556 (13.6) 803 (18.0)
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Table 2 Characteristics of patients by centre in the complete case data (Continued)
Pulmonary disease
No 10,991 (88.4) 3,499 (85.5) 3,926 (87.9)
Yes 1,444 (11.6) 593 (14.5) 542 (12.1)
Neurological disease
No 11,303 (90.9) 3,790 (92.6) 4,077 (91.2)
Yes 1,132 (9.1) 302 (7.4) 391 (8.8)
Hypertensionc
No 4,400 (35.4) 1,307 (31.9) 1,673 (37.4)
Yes 8,035 (64.6) 2,785 (68.1) 2,795 (62.6)
Haemoglobin
<10.0 218 (1.8) 91 (2.2) 71 (1.6)
10.0 to11.9 1,487 (12.0) 593 (14.5) 515 (11.5)
12.0+ 10,730 (86.3) 3,408 (83.3) 3,882 (86.9)
GFR
<30.0 436 (3.5) 102 (2.5) 54 (1.2)
30.0 to 59.9 4,592 (36.9) 1,460 (35.7) 1,059 (23.7)
60.0 to 89.9 5,458 (43.9) 1,741 (42.5) 1,887 (42.2)
90.0+ 1,949 (15.7) 789 (19.3) 1,468 (32.9)
Heparin or nitrates
None 10,724 (86.2) 3,595 (87.9) 4,133 (92.5)
Within a week 914 (7.4) 53 (1.3) 114 (2.6)
At operation 797 (6.4) 444 (10.9) 221 (4.9)
Critical preoperative event
No 12,268 (98.7) 3,944 (96.4) 4,392 (98.3)
Yes 167 (1.3) 148 (3.6) 76 (1.7)
Catheter to surgery
Within 24 h 299 (2.4) 38 (0.9) 84 (1.9)
>24 h this admission 6,825 (54.9) 1,019 (24.9) 971 (21.7)
>24 h previous admission 5,311 (42.7) 3,035 (74.2) 3,413 (76.4)
Triple vessel disease
No 6,041 (48.6) 1,759 (43.0) 1,819 (40.7)
Yes 6,394 (51.4) 2,333 (57.0) 2,649 (59.3)
Left main stem disease
No 10,208 (82.1) 3,162 (77.3) 3,422 (76.6)
Yes 2,227 (17.9) 930 (22.7) 1,046 (23.4)
Ejection fraction
Good (50+ %) 9,111 (73.3) 2,758 (67.4) 2,910 (65.1)
Fair (30 to 49%) 2,668 (21.5) 1,143 (27.9) 1,192 (26.7)
Poor (<30%) 656 (5.3) 191 (4.7) 366 (8.2)
Operative priority
Elective 7,350 (59.1) 2,798 (68.4) 3,173 (71.0)
Urgent 4,896 (39.4) 1,256 (30.7) 1,255 (28.1)
Emergency/salvage 189 (1.5) 38 (0.9) 40 (0.9)
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Table 2 Characteristics of patients by centre in the complete case data (Continued)
Cardiac procedures
CABG only 8,587 (69.1) 2,241 (54.8) 2,974 (66.6)
Valve only 1,838 (14.8) 644 (15.7) 622 (13.9)
CABG+valve 1,169 (9.4) 554 (13.5) 568 (12.7)
Other/multiple 841 (6.8) 653 (16.0) 304 (6.8)
Acute kidney injury, %
None 9,495 (76.4) 3,238 (79.1) 3,370 (75.4)
Stage 1 2,164 (17.4) 560 (13.7) 706 (15.8)
Stage 2 330 (2.7) 89 (2.2) 124 (2.8)
Stage 3 446 (3.6) 205 (5.0) 268 (6.0)
aCanadian Cardiovascular Society (CCS) classes: 1 ordinary activity does not cause angina; 2 slight limitation; 3 marked limitation; 4 inability to carry out any
physical activity without discomfort. bNew York Heart Association (NYHA) functional classification: 1 no symptoms and no limitation in ordinary physical activity;
2 mild symptoms and slight limitation during ordinary activity; 3 marked limitation in activity due to symptoms, comfortable only at rest; 4 severe limitations,
experiences symptoms even while at rest. cHypertension was defined as treated or blood pressure >140/90. CABG, coronary artery bypass graft; GFR, glomerular
filtration rate; Haemoglobin, g/dL; GFR, mL/min.
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Characteristics of patients
Data were available from 18,686 patients from Bristol
and 7,306 patients from Birmingham (the developmental
sample) and 4,862 patients from Wolverhampton
(the validation sample). Missing data for each centre
are reported in Table 1. The most common field that
was missing was the baseline Hb. This was missing
in 39% of the Birmingham data, and predominantly in the
years prior to 2004. Emergency/salvage surgery were more
likely to have missing preoperative creatinine (Bristol 10%,
Birmingham 14%, Wolverhampton 3% missing) compared
to elective or urgent surgery (Bristol 1%, Birmingham 1%,
Wolverhampton 0% missing). The complete case analysis
included 20,995 patients, of whom 12,435 were from
Bristol, 4,092 were from Birmingham and 4,468 were
from Wolverhampton (Table 2).
In the complete case data median age by centre was:
Bristol 68 years (IQR 60, 74), Birmingham 67 years (59, 73)
and Wolverhampton 67 years (60, 74). The majority ofTable 3 Total patients who met different acute kidney injury





No RRT <1.5 16,094a
1.5 to 1.9 1b
2.0 to 2.9
≥3.0




Creatinine measure in μmol/L. aNo AKI, total = 16,103; bstage-1 AKI, total = 3,430; cstoperations were performed on men (76.2% in Bristol, 73.1%
in Birmingham and 76.5% in Wolverhampton). The most
common procedure was CABG only (69.1% in Bristol,
54.8% in Birmingham and 66.6% in Wolverhampton).
Mean (SD) baseline creatinine values by centre were Bristol
108.9 μmol/L (28.5), Birmingham 107.1 μmol/L (34.4) and
Wolverhampton 94.8 μmol/L (28.4) Any stage of AKI
affected 23.7% patients in the Bristol dataset, 20.9% patients
in Birmingham and 24.6% patients in Wolverhampton.
Stage-3 AKI was slightly more prevalent in the validation
dataset (6.0%) compared to the development sample
(3.6% in Bristol and 5.0% in Birmingham). The criteria by
which patients were defined as having AKI are described
in Table 3.
KDIGO-defined AKI severity and outcome
AKI was associated with increased hospital stay (Table 4).
Patients without AKI had a median postoperative hospital
stay of 6 days in Bristol (IQR 5, 8) and Wolverhampton
(5, 7), and 9 days (6, 13) in Birmingham (Table 4).(AKI) criteria in the complete case data











age-2 AKI, total = 543; dstage-3 AKI, total = 919. RRT, renal replacement therapy.
Table 4 Length of stay following surgery by acute kidney injury (AKI) status
Bristol Birmingham Wolverhampton
Numbe Median IQR Number Median IQR Number Median IQR
All patients
AKI
None 9495 6 (5, 8) 3238 9 (6, 13) 3370 6 (5, 7)
Stage 1 2164 9 (7, 13) 560 13 (9, 19) 706 8 (6, 13)
Stage 2 330 11 (8, 16) 89 19 (12, 32) 124 10 (8, 17)
Stage 3 446 14 (10, 26) 205 19 (10, 42) 268 16 (9, 32)
Patients who did not die in hospital
AKI
None 9464 6 (5, 8) 3205 9 (7, 13) 3357 6 (5, 7)
Stage 1 2119 9 (7, 13) 544 13 (9, 18) 693 8 (6, 13)
Stage 2 313 11 (8, 16) 88 19 (12, 32) 122 10 (8, 17)
Stage 3 338 15 (10, 27) 133 25 (14, 43) 190 17 (11, 32)
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stay increased to 9 days (IQR 7, 13) in Bristol, 13 (9, 19) in
Birmingham and 8 (6, 13) in Wolverhampton. Patients
with the most severe AKI (stages 2 and 3) had the longest
postoperative stay. In the complete case data (n = 20,995)
stage-1 AKI was associated with higher odds of infective
and pulmonary complications and an almost five-fold
increase in the odds of death in hospital (Table 5).
Odds ratios for stage-3 AKI compared to no AKI
were 7.6 (95% CI 6.6, 8.8) for infective complications,
9.4 (8.2, 10.8) for pulmonary complications and 81.2
(62.3, 106.0) for death in hospital. Over 80% of all
deaths in hospital were preceded by AKI.
Model building for the clinical prediction score
A total of 23 factors were examined for their associations
with AKI. Odds ratios for unadjusted and fully adjusted
models are presented in Table 6 (for models of any-stage
AKI) and Table 7 (for models of stage-3 AKI). In fully
adjusted models, 15 factors were strongly associated with
any-stage AKI (P <0.001) and were included in the initial
prognostic model. A further five factors were associated
with any-stage AKI at the level of P <0.05, and were added
to the more inclusive model. For stage-3 AKI, eight factorsTable 5 Outcomes following surgery by acute kidney injury (A
AKI status Total number Infective complication Pulm
Number (%) Odds ratio (95% CI) Num
None 16103 1430 (8.9) 1 1810
Stage 1 3430 623 (18.2) 2.3 (2.1, 2.5) 793
Stage 2 543 133 (24.5) 3.3 (2.7, 4.1) 192
Stage 3 919 392 (42.7) 7.6 (6.6, 8.8) 500
P-value <0.001
P-values for trend derived from logistic regression models.were included in the initial prognostic model (P <0.001), a
further three factors were included in the more inclusive
prognostic model (P <0.05).
Diagnostic utility
Any-stage AKI score
The ROC AUC for the initial model for any-stage AKI
in the development sample was 0.73 (95% CI 0.72, 0.74;
Figure 1 and Table 8) and was very similar in the validation
sample (AUC 0.74; 95% CI 0.72, 0.76). The Hosmer
Lemshow test (P = 0.490, Table 9) and plot of observed
versus predicted any-stage AKI (Figure 2A and Table 9)
demonstrated good calibration in the development sample.
The initial model was less well-calibrated in the validation
sample (Hosmer Lemshow P = 0.192, and Figure 2B).
The more inclusive model did not demonstrate better
discrimination when compared to the initial model
(Table 8), however, it did demonstrate better calibration as
evidenced by the Hosmer-Lemeshow test (P = 0.406 in the
validation sample) and plots of observed versus predicted
any-stage AKI (Figure 2B and Table 9).
For the validation sample discrimination by the any-stage
AKI score was better than the Euroscore (AUC 0.68; 95%
CI 0.67, 0.70) and Cleveland clinic (AUC 0.70; 95% CI 0.69,KI) status, data from all centres
onary complication Died in hospital
ber (%) Odds ratio (95% CI) Number (%) Odds ratio (95% CI)
(11.2) 1 77 (0.5) 1
(23.1) 2.4 (2.2, 2.6) 74 (2.2) 4.6 (3.3, 6.3)
(35.4) 4.3 (3.6, 5.2) 20 (3.7) 8.0 (4.8, 13.1)
(54.4) 9.4 (8.2, 10.8) 258 (28.1) 81.2 (62.3, 106.0)
<0.001 <0.001
Table 6 Associations of preoperative factors with any-stage acute kidney injury (AKI) in the development sample
(Bristol and Birmingham)
Number Number (%) Unadjusted Fully adjusted
Total Any AKI Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Demographic factors
Age, years
<60 4,056 485 (12.0) 1.00 1.00
60 to 74 9,074 2,039 (22.5) 2.13 (1.92, 2.37) 1.53 (1.35, 1.74)
≥75 3,397 1,270 (37.4) 4.40 (3.91, 4.94) <0.001 2.21 (1.91, 2.57) <0.001
Sex
Male 12,464 2,891 (23.2) 1.00 1.00
Female 4,063 903 (22.2) 0.95 (0.87, 1.03) 0.202 0.53 (0.48, 0.59) <0.001
Body mass index
<20.0 594 175 (29.5) 1.60 (1.33, 1.92) 0.80 (0.64, 0.99)
20.0 to 24.9 4,209 931 (22.1) 1.08 (0.99, 1.19) 0.79 (0.71, 0.88)
25.0 to -29.9 7,422 1,540 (20.7) 1.00 1.00
30.0 to 34.9 3,258 854 (26.2) 1.36 (1.23, 1.49) 1.75 (1.57, 1.95)
35.0+ 1,044 294 (28.2) 1.50 (1.29, 1.73) <0.001 2.11 (1.78, 2.50) <0.001
Smoking status
Never smoked 5,321 1,122 (21.1) 1.00 1.00
Ex-smoker 9,499 2,315 (24.4) 1.21 (1.11, 1.31) 1.09 (1.00, 1.20)
Current smoker 1,707 357 (20.9) 0.99 (0.87, 1.13) <0.001 1.41 (1.22, 1.64) <0.001
Preoperative factors
Angina
No angina 3,083 810 (26.3) 1.00 1.00
CCS 1 1,859 409 (22.0) 0.79 (0.69, 0.91) 0.84 (0.73, 0.98)
CCS 2 4,965 994 (20.0) 0.70 (0.63, 0.78) 0.79 (0.69, 0.90)
CCS 3 3,834 870 (22.7) 0.82 (0.74, 0.92) 0.80 (0.70, 0.92)
CCS 4 2,786 711 (25.5) 0.96 (0.86, 1.08) <0.001 0.75 (0.64, 0.87) 0.002
Dyspnoea
NYHA 1 3,583 610 (17.0) 1.00 1.00
NHYA 2 7,223 1,465 (20.3) 1.24 (1.12, 1.38) 1.07 (0.95, 1.19)
NYHA 3 4,823 1,360 (28.2) 1.91 (1.72, 2.13) 1.29 (1.14, 1.46)
NYHA 4 898 359 (40.0) 3.25 (2.77, 3.81) <0.001 1.37 (1.13, 1.66) <0.001
Previous MI
0 10,457 2,272 (21.7) 1.00 1.00
1 4,928 1,174 (23.8) 1.13 (1.04, 1.22) 0.99 (0.90, 1.10)
≥2 1,142 348 (30.5) 1.58 (1.38, 1.81) <0.001 1.04 (0.88, 1.21) 0.879
Previous operations
0 15,835 3,578 (22.6) 1.00 1.00
1+ 692 216 (31.2) 1.55 (1.32, 1.83) <0.001 1.39 (1.15, 1.67) 0.007
Preoperative diabetes
No 13,419 2,824 (21.0) 1.00 1.00
Yes 3,108 970 (31.2) 1.70 (1.56, 1.86) <0.001 1.41 (1.28, 1.55) <0.001
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Table 6 Associations of preoperative factors with any-stage acute kidney injury (AKI) in the development sample
(Bristol and Birmingham) (Continued)
Peripheral vascular disease
No 14,924 3,237 (21.7) 1.00 1.00
Yes 1,603 557 (34.7) 1.92 (1.72, 2.15) <0.001 1.31 (1.16, 1.48) <0.001
Pulmonary disease
No 14,490 3,217 (22.2) 1.00 1.00
Yes 2,037 577 (28.3) 1.38 (1.25, 1.54) <0.001 1.07 (0.96, 1.20) 0.240
Neurological disease
No 15,093 3,346 (22.2) 1.00 1.00
Yes 1,434 448 (31.2) 1.60 (1.42, 1.80) <0.001 1.14 (1.00, 1.30) 0.044
Hypertension
No 5,707 1,028 (18.0) 1.00 1.00
Yes 10,820 2,766 (25.6) 1.56 (1.44, 1.69) <0.001 1.28 (1.17, 1.40) <0.001
Haemoglobin
<10.0 309 133 (43.0) 2.98 (2.37, 3.74) 1.58 (1.23, 2.04)
10.0 to11.9 2,080 800 (38.5) 2.46 (2.23, 2.72) 1.67 (1.49, 1.87)
12.0+ 14,138 2,861 (20.2) 1.00 <0.001 1.00 <0.001
Glomerular filtration rate
<30.0 538 283 (52.6) 5.64 (4.71, 6.75) 4.64 (3.73, 5.77)
30.0 to 59.9 6,052 1,917 (31.7) 2.36 (2.17, 2.56) 2.25 (2.03, 2.48)
60.0 to 89.9 7,199 1,184 (16.4) 1.00 1.00
90.0+ 2,738 410 (15.0) 0.89 (0.79, 1.01) <0.001 0.82 (0.71, 0.95) <0.001
Heparin or nitrates
None 14,319 3,086 (21.6) 1.00 1.00
Within a week 967 299 (30.9) 1.63 (1.41, 1.88) 1.31 (1.11, 1.55)
At operation 1,241 409 (33.0) 1.79 (1.58, 2.03) <0.001 1.27 (1.08, 1.48) 0.001
Critical preoperative event
No 16,212 3,640 (22.5) 1.00
Yes 315 154 (48.9) 3.30 (2.64, 4.13) <0.001 1.57 (1.19, 2.06) 0.002
Catheter to surgery
Within 24 h 337 125 (37.1) 1.95 (1.55, 2.44) 1.17 (0.87, 1.57)
>24 h this admission 7,844 1,730 (22.1) 0.93 (0.87, 1.01) 0.80 (0.72, 0.88)
>24 h prev admission 8,346 1,939 (23.2) 1.00 <0.001 1.00 <0.001
Triple vessel disease
No 7,800 1,697 (21.8) 1.00 1.00
Yes 8,727 2,097 (24.0) 1.14 (1.06, 1.22) <0.001 1.24 (1.12, 1.37) <0.001
Left main stem disease
No 13,370 3,014 (22.5) 1.00
Yes 3,157 780 (24.7) 1.13 (1.03, 1.23) <0.001 1.00 (0.90, 1.11) 0.986
Ejection fraction
Good (50+ %) 11,869 2,362 (19.9) 1.00 1.00
Fair (30 to 49%) 3,811 1,121 (29.4) 1.68 (1.54, 1.82) 1.22 (1.11, 1.34)
Poor (<30%) 847 311 (36.7) 2.34 (2.02, 2.70) <0.001 1.34 (1.13, 1.59) <0.001
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Table 6 Associations of preoperative factors with any-stage acute kidney injury (AKI) in the development sample
(Bristol and Birmingham) (Continued)
Operative priority
Elective 10,148 2,043 (20.1) 1.00 1.00
Urgent 6,152 1,644 (26.7) 1.45 (1.34, 1.56) 1.33 (1.20, 1.48)
Emergency/Salvage 227 107 (47.1) 3.54 (2.71, 4.61) <0.001 1.93 (1.34, 2.76) <0.001
Cardiac procedures
CABG only 10,828 2,167 (20.0) 1.00 1.00
Valve only 2,482 553 (22.3) 1.15 (1.03, 1.27) 1.27 (1.08, 1.48)
CABG+valve 1,723 644 (37.4) 2.39 (2.14, 2.66) 1.81 (1.59, 2.07)
Other/multiple 1,494 430 (28.8) 1.62 (1.43, 1.82) <0.001 1.62 (1.39, 1.89) <0.001
CCS, Canadian Cardiovascular Society; NYHA, New York Heart Association; MI, myocardial infarction; prev, previous; CABG, coronary artery bypass graft; Haemoglobin, g/dL; GFR, mL/min.
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0.76) and Ng score (AUC 0.73; 95% CI 0.71, 0.75) (Table 8).
Hosmer-Lemshow tests and calibration plots (Table 9 and
Figure 2B) demonstrated that the more inclusive model
demonstrated better calibration than each of the four
comparison scores.
Stage-3 AKI score
In the validation sample both the initial prognostic
stage-3 AKI model (0.78, 95% CI 0.75, 0.80) and the more
inclusive stage-3 AKI model (0.79, 95% CI 0.76, 0.81)
demonstrated good discrimination (Figure 1 and Table 8).
The stage-3 AKI score had better discrimination than
the Euroscore (0.73; 95% CI 0.70, 0.76) and similar
discrimination to the Cleveland Clinic (0.78; 95% CI
0.75, 0.81), Metha score (0.79; 95% CI 0.77, 0.82) and
Ng Score (0.79, 95% CI 0.76, 0.82) (Table 8). Plots of
observed versus expected stage-3 AKI indicated that
the initial stage-3 AKI model had better calibration
that each of the four comparison scores, however
Hosmer-Lemshow tests suggested that calibration of
the stage-3 score, as well as the four comparison scores
was poor (P <0.001) in both development and validation
samples (Figure 2C, D).
Final model coefficients
The model coefficients for the initial model for any-stage
AKI and the initial model for stage-3 AKI are shown in
Table 10. Factors associated with any-stage AKI in the
final model were older age, male sex, BMI >35 kg/m2,
current smokers, higher dyspnoea categories, diabetes,
peripheral vascular disease, hypertension, lower haemo-
globin, lower estimated GFR, catheter to surgery within
24 hours, triple vessel disease, poor ejection fraction,
emergency/salvage operations and more complex surgery.
The only factor included in the stage-3 model that was
not in the any-stage model was a critical preoperative
event. Sensitivity analyses showed that adding two-way
interactions at P <0.05 did not improve the diagnosticutility in the validation sample (data not shown). Further
sensitivity analysis using only more recent data (after
2002) did not improve discrimination. Coefficients from
imputed data for the final model were very similar to the
complete case analysis (data not shown).
Discussion
This study has developed two new risk scores for the
preoperative identification of cardiac surgery patients
who are at increased risk of developing AKI. These
scores were developed using a large cohort of patients
from two UK cardiac centres and externally validated
using data from a third UK centre. We compared the
diagnostic utility of these scores to four previously
published scores; Euroscore, Mehta Score, Cleveland
Clinic score and the Ng score. Our risk prediction score
for any-stage AKI has demonstrated better discrimination
compared to the Euroscore and the Cleveland Clinic
Score, and equivalent discrimination to the Mehta and Ng
scores. The any-stage AKI score demonstrated better cali-
bration than the four comparison scores. The stage-3 AKI
risk prediction score demonstrated good discrimination,
as did the four comparison risk scores, but these scores
were less well-calibrated.
The study has important strengths. It has demonstrated
the prognostic utility of the KDIGO AKI definition in a
large multicentre cohort, and has confirmed the prognostic
importance of milder forms of AKI, as has been identified
by earlier consensus definitions [12,13]. The two risk scores
we have developed are the first to our knowledge that have
been designed to predict a consensus definition of AKI.
The use of consensus AKI definitions as endpoints is
a key element of study design that is important for
standardisation of reporting and comparative analyses
of trials. Furthermore, the any-stage AKI risk score is
the first externally validated AKI risk prediction score
that has been designed to include patients at risk of
KDIGO stage-1 AKI, which we have shown to have
prognostic utility in the current study. The any-stage
Table 7 Associations of preoperative factors with stage-3 acute kidney injury (AKI) in the Bristol and Birmingham
development sample (complete case data)
Number Number (%) Unadjusted Fully adjusted
Total Stage-3 AKI Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Demographic factors
Age, years
<60 4,056 75 (1.8) 1.00 1.00
60 to 74 9,074 352 (3.9) 2.14 (1.66, 2.76) 1.25 (0.94, 1.66)
≥75 3,397 224 (6.6) 3.75 (2.87, 4.89) <0.001 1.29 (0.94, 1.78) 0.255
Sex
Male 12,464 497 (4.0) 1.00 1.00
Female 4,063 154 (3.8) 0.95 (0.79, 1.14) 0.575 0.45 (0.36, 0.55) <0.001
Body mass index
<20.0 594 31 (5.2) 1.57 (1.07, 2.31) 0.54 (0.35, 0.84)
0.0 to 24.9 4,209 177 (4.2) 1.25 (1.03, 1.53) 0.83 (0.67, 1.03)
25.0 to 29.9 7,422 251 (3.4) 1.00 1.00
30.0 to 34.9 3,258 137 (4.2) 1.25 (1.01, 1.55) 1.79 (1.42, 2.26)
35.0+ 1,044 55 (5.3) 1.59 (1.18, 2.14) 0.006 2.60 (1.85, 3.65) <0.001
Smoking status
Never smoked 5,321 193 (3.6) 1.00 1.00
Ex-smoker 9,499 402 (4.2) 1.17 (0.99, 1.40) 1.11 (0.92, 1.35)
Current smoker 1,707 56 (3.3) 0.90 (0.67, 1.22) 0.061 1.35 (0.97, 1.88) 0.191
Pre-operative factors
Angina
No angina 3,083 176 (5.7) 1.00 1.00
CCS 1 1,859 76 (4.1) 0.70 (0.53, 0.93) 0.79 (0.59, 1.06)
CCS 2 4,965 142 (2.9) 0.49 (0.39, 0.61) 0.68 (0.52, 0.89)
CCS 3 3,834 135 (3.5) 0.60 (0.48, 0.76) 0.74 (0.56, 0.98)
CCS 4 2,786 122 (4.4) 0.76 (0.60, 0.96) <0.001 0.79 (0.59, 1.06) 0.047
Dyspnoea
NYHA 1 3,583 87 (2.4) 1.00 1.00
NHYA 2 7,223 217 (3.0) 1.24 (0.97, 1.60) 1.02 (0.78, 1.32)
NYHA 3 4,823 242 (5.0) 2.12 (1.66, 2.72) 1.23 (0.94, 1.63)
NYHA 4 898 105 (11.7) 5.32 (3.96, 7.14) <0.001 1.47 (1.02, 2.10) 0.063
Previous MI
0 10,457 379 (3.6) 1.00 1.00
1 4,928 200 (4.1) 1.12 (0.94, 1.34) 1.06 (0.86, 1.31)
≥2 1,142 72 (6.3) 1.79 (1.38, 2.32) <0.001 1.18 (0.86, 1.61) 0.581
Previous operations
0 15,835 596 (3.8) 1.00 1.00
1+ 692 55 (7.9) 2.21 (1.66, 2.94) <0.001 1.59 (1.15, 2.19) 0.006
Preoperative diabetes
No 13,419 443 (3.3) 1.00 1.00
Yes 3,108 208 (6.7) 2.10 (1.77, 2.49) <0.001 1.80 (1.48, 2.18) <0.001
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Table 7 Associations of preoperative factors with stage-3 acute kidney injury (AKI) in the Bristol and Birmingham
development sample (complete case data) (Continued)
Peripheral vascular disease
No 14,924 554 (3.7) 1.00 1.00
Yes 1,603 97 (6.1) 1.67 (1.34, 2.09) <0.001 1.07 (0.84, 1.37) 0.582
Pulmonary disease
No 14,490 548 (3.8) 1.00 1.00
Yes 2,037 103 (5.1) 1.35 (1.09, 1.68) 0.006 1.02 (0.81, 1.28) 0.889
Neurological disease
No 15,093 579 (3.8) 1.00 1.00
Yes 1,434 72 (5.0) 1.33 (1.03, 1.70) 0.028 0.95 (0.72, 1.24) 0.685
Hypertension
No 5,707 196 (3.4) 1.00 1.00
Yes 10,820 455 (4.2) 1.23 (1.04, 1.46) 0.016 1.00 (0.83, 1.22) 0.972
Haemoglobin
<10.0 309 45 (14.6) 5.79 (4.16, 8.07) 2.34 (1.59, 3.42)
10.0 to 11.9 2,080 202 (9.7) 3.66 (3.07, 4.36) 2.17 (1.78, 2.66)
12.0+ 14,138 404 (2.9) 1.00 <0.001 1.00 <0.001
Glomerular filtration rate
<30.0 538 98 (18.2) 8.89 (6.82, 11.59) 8.64 (6.14, 12.15)
30.0 to 59.9 6,052 337 (5.6) 2.35 (1.95, 2.83) 2.37 (1.91, 2.94)
60.0 to 89.9 7,199 176 (2.4) 1.00 1.00
90+ 2,738 40 (1.5) 0.59 (0.42, 0.84) <0.001 0.46 (0.32, 0.67) <0.001
Heparin or nitrates
None 14,319 510 (3.6) 1.00 1.00
Within a week 967 50 (5.2) 1.48 (1.10, 1.99) 1.00 (0.71, 1.42)
At operation 1,241 91 (7.3) 2.14 (1.70, 2.70) <0.001 1.20 (0.90, 1.61) 0.486
Critical preoperative event
No 16,212 591 (3.6) 1.00
Yes 315 60 (19.0) 6.22 (4.64, 8.34) <0.001 2.44 (1.63, 3.66) <0.001
Catheter to surgery
Within 24 h 337 40 (11.9) 3.02 (2.14, 4.28) 1.28 (0.78, 2.08)
>24 h this admission 7,844 255 (3.3) 0.75 (0.64, 0.89) 0.55 (0.45, 0.68)
>24 h previous admission 8,346 356 (4.3) 1.00 <0.001 1.00 <0.001
Triple vessel disease
No 7,800 315 (4.0) 1.00 1.00
Yes 8,727 336 (3.9) 0.95 (0.81, 1.11) 0.534 1.22 (0.98, 1.52) 0.075
Left main stem disease
No 13,370 520 (3.9) 1.00 1.00
Yes 3,157 131 (4.1) 1.07 (0.88, 1.30) 0.499 1.09 (0.87, 1.36) 0.461
Ejection fraction
Good (50+ %) 11,869 367 (3.1) 1.00 1.00
Fair (30 to 49%) 3,811 204 (5.4) 1.77 (1.49, 2.11) 1.07 (0.88, 1.30)
Poor (<30%) 847 80 (9.4) 3.27 (2.54, 4.21) <0.001 1.32 (0.98, 1.80) 0.206
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Table 7 Associations of preoperative factors with stage-3 acute kidney injury (AKI) in the Bristol and Birmingham
development sample (complete case data) (Continued)
Operative priority
Elective 10,148 323 (3.2) 1.00 1.00
Urgent 6,152 295 (4.8) 1.53 (1.30, 1.80) 1.51 (1.20, 1.88)
Emergency/Salvage 227 33 (14.5) 5.17 (3.52, 7.61) <0.001 1.36 (0.75, 2.46) 0.002
Cardiac procedures
CABG only 10,828 294 (2.7) 1.00 1.00
Valve only 2,482 102 (4.1) 1.54 (1.22, 1.93) 1.45 (1.05, 2.01)
CABG+valve 1,723 135 (7.8) 3.05 (2.47, 3.76) 2.02 (1.57, 2.61)
Other/multiple 1,494 120 (8.0) 3.13 (2.51, 3.90) <0.001 2.69 (2.02, 3.57) <0.001
CCS, Canadian Cardiovascular Society; NYHA, New York Heart Association; MI, myocardial infarction; CABG, coronary artery bypass graft; Haemoglobin, g/dL; GFR, mL/min.
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that is freely available to any researcher or clinician.
It can be accessed by any smart phone, tablet or
tabletop computer, and can be completed in less than
1 minute. Using a cutoff for the any-stage AKI score
of 30% will select patients for interventional studies
with a positive predictive value of 44% and a negative
predictive value of 85% for AKI. We suggest that this
score may be used to identify an enriched patient cohort
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Figure 1 Receiver operating characteristic curves for the any-stage ac
external validation dataset (Wolverhampton data).advantage for our stage-3 AKI score in relation to existing
scores. The stage-3 AKI score may have greater utility
as a risk adjustment tool for quality assurance, or
clinically to assist with informed consent. However it
did not demonstrate clear advantages beyond existing
score and we have not developed a web-based calculator
for this score.
The study has several limitations. First, retrospective
analyses of routinely collected data have limitations with
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Stage 3 AKI, more inclusive model
cificity
ute kidney injury (AKI) and stage-3 AKI risk models in the
Table 8 Discrimination: area under ROC curves for the different scores and for different procedures (complete case data)
Area under the curve (95% CI)
Development sample Bristol and Birmingham n = 16,527 Validation sample Wolverhampton n = 4,468
Any-stage AKI Stage-3 AKI Any-stage AKI Stage-3 AKI
Initial model (P <0.001) 0.73 (0.72, 0.74) 0.79 (0.77, 0.80) 0.74 (0.72, 0.76) 0.78 (0.75, 0.80)
More inclusive model (P <0.05) 0.74 (0.73, 0.75) 0.79 (0.78, 0.81) 0.74 (0.72, 0.76) 0.79 (0.76, 0.81)
Comparison Scores
Euroscore 0.66 (0.65, 0.67) 0.71 (0.69, 0.73) 0.68 (0.66, 0.70) 0.73 (0.70, 0.76)
Cleveland clinic 0.65 (0.64, 0.66) 0.74 (0.72, 0.76) 0.70 (0.69, 0.72) 0.78 (0.75 0.81)
Metha score 0.71 (0.70, 0.72) 0.79 (0.77, 0.80) 0.74 (0.72, 0.76) 0.79 (0.77, 0.82)
Ng score 0.70 (0.69, 0.71) 0.77 (0.75, 0.79) 0.73 (0.71, 0.75) 0.79 (0.76, 0.82)
Procedure type
Coronary artery bypass graft only 0.73 (0.72, 0.74) 0.78 (0.75, 0.81) 0.72 (0.70, 0.74) 0.78 (0.73, 0.82)
Valve only 0.72 (0.70, 0.74) 0.75 (0.70, 0.80) 0.73 (0.69, 0.77) 0.78 (0.72, 0.84)
Coronary artery bypass graft + valve 0.70 (0.66, 0.72) 0.74 (0.70, 0.79) 0.71 (0.67, 0.75) 0.70 (0.62, 0.76)
Other/multiple 0.70 (0.67, 0.73) 0.69 (0.64, 0.74) 0.70 (0.64, 0.76) 0.72 (0.62, 0.81)
P-values to compare diagnostic utility between our score and existing scores in validation sample for any acute kidney injury (AKI): Euroscore P <0.001; Cleveland
clinic P <0.001; Metha score P = 0.807; Ng score P = 0.172. For stage-3 AKI: Euroscore P = 0.002; Cleveland clinic P = 0.801; Metha score P = 0.173; Ng score P = 0.384.
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individuals and sites. To minimise these we used prospect-
ively collected data from three clinical databases that use
common, standardised definitions for clinical risk factors.
The data had undergone both internal and external quality
checking, had low levels of missing data, and the
three sites contributing to the study are listed asTable 9 Calibration: Hosmer Lemshow tests and results of lin
calibration plots
Development sample Bristol and Birmin
Any-stage AKI Stage-3 A
Hosmer-Lemeshow P-valuesa P P
Initial model (P <0.001) 0.490 0.001
More inclusive model (P <0.05) 0.784 <0.001
Euroscore <0.001 <0.001
Cleveland clinic 0.112 <0.001
Metha score 0.009 <0.001
Ng score 0.013 <0.001
Any-stage AKI Stage-3 A
Slope and interceptb Slope Intercept Slope
Initial model (P <0.001) 1.045 -0.007 1.094
More inclusive model (P <0.05) 1.050 -0.008 1.334
Euroscore 1.050 -0.009 1.145
Cleveland clinic 1.283 -0.048 1.145
Metha score 1.144 -0.029 1.513
Ng score 1.130 -0.021 1.378
aHigher values indicate better calibration. bSlope and intercept from linear regressio
Figure 2. The closer the slope is to 1, and the closer the intercept is to 0, indicates bamong the top for data quality within the UK
NACSA programme. Importantly, baseline creatinine
values, defined in this study as the preoperative value
obtained closest to the date of operation, were present in
over 98% of patients, as would be expected in a cardiac
surgery cohort where preoperative bloods are rou-
tinely taken in all but the very sickest patients. Thisear regression analysis of observed versus expected
gham n = 16,527 Validation sample Wolverhampton n = 4,468








KI Any-stage AKI Stage-3 AKI
Intercept Slope Intercept Slope Intercept
-0.002 1.152 -0.009 1.529 0.009
-0.007 1.140 -0.001 2.088 -0.003
-0.004 1.152 -0.038 1.789 -0.016
-0.004 1.927 -0.138 3.376 -0.033
-0.013 1.348 -0.040 2.199 -0.010
-0.008 1.338 -0.010 2.196 -0.004
n analysis of observed versus expected values analysed by decile, as plotted in
etter calibration.
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Figure 2 Calibration plots of observed versus expected
values for the any-stage acute kidney injury (AKI), stage-3 AKI,
Cleveland, Mehta, Ng score and EuroScore in the development
(Bristol, Birmingham) and validation (Wolverhampton) datasets.
(A) Any-stage AKI, Bristol and Birmingham. (B) Any-stage AKI,
Wolverhampton. (C) Stage-3 AKI, Bristol and Birmingham. (D) Stage-3
AKI, Wolverhampton.
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http://ccforum.com/content/18/6/606is important; alternate definitions of baseline change
the reported frequency of stage-1 AKI [25] - a key
consideration in this study. The only variable for
which there was a significant proportion of missing data
was baseline haemoglobin, and this was restricted to a
single centre. To address the limitations posed by missing
data we performed our primary analysis in the complete
case data. We confirmed the robustness of the models de-
veloped in the complete case analysis in imputed
data. Model coefficients do not differ substantially in the
imputed data, which suggests that the missing data are un-
likely to have introduced bias into our model.
Second, unmeasured confounders are an important
consideration in any retrospective analysis. For example,
the Bristol and Birmingham databases do not routinely
record patient race, and this has been found to be an
important variable in some risk scores but not others
[6]. This may also have affected the estimated GFR
(eGFR) calculation, a key component of the score. Equations
to calculate eGFR that include race, such as, for example,
the modified diet in renal disease equation [26] have greater
accuracy.
Third, intra and postoperative events that affect the
incidence of AKI also represent confounders [10,27].
However, it was our intention to design a score that
will identify patients at risk of AKI preoperatively on the
basis that the most effective prevention strategies are
likely to be those applied before or at the commencement
of surgery rather than after injury (surgery) has occurred.
Fourth, the AKI definition used did not incorporate urine
output data, as defined in the KDIGO definition, as these
data were not recorded. Urine output data are known to
significantly alter the estimates in patients with AKI,
although whether this improves the prognostic utility of
the scores is unclear particularly in cardiac surgery, where
perioperative urine output is closely monitored, and
oliguria aggressively treated [28]. The use of creatinine-
based definitions of AKI has other limitations in cardiac
surgery. In the validation sample in this study 48% of
patients had undergone coronary angiography within
the same hospital admission and 39% were undergo-
ing urgent inpatient surgery. Many of these patients
would have sustained significant renal insults prior to
surgery and this may have increased the baseline
serum creatinine value.
Table 10 Model coefficients for final models (complete case data)
Any-stage AKI Stage-3 AKI
Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Age, years
<60 1.00
60 to 74 1.53 (1.35, 1.73)
≥75 2.19 (1.89, 2.54) <0.001
Sex
Male 1.00 1.00
Female 0.53 (0.48, 0.59) <0.001 0.42 (0.34, 0.51) <0.001
Body mass index
<20.0 0.80 (0.64, 0.99) 0.54 (0.35, 0.82)
20.0 to 24.9 0.80 (0.72, 0.88) 0.84 (0.68, 1.04)
25.0 to 29.9 1.00 1.00
30.0 to 34.9 1.75 (1.57, 1.95) 1.81 (1.44, 2.27)
35.0+ 2.08 (1.76, 2.47) <0.001 2.71 (1.94, 3.79) <0.001
Smoking status
Never smoked 1.00
Ex smoker 1.09 (1.00, 1.20)
Current smoker 1.41 (1.22, 1.64) <0.001
Dyspnoea
NYHA 1 1.00
NHYA 2 1.05 (0.94, 1.17)
NYHA 3 1.29 (1.14, 1.45)
NYHA 4 1.44 (1.20, 1.74) <0.001
Preoperative diabetes
No 1.00 1.00
Yes 1.40 (1.27, 1.55) <0.001 1.91 (1.59, 2.31) <0.001
Peripheral vascular disease
No 1.00
Yes 1.35 (1.20, 1.52) <0.001
Hypertension
No 1.00
Yes 1.28 (1.17, 1.40) <0.001
Haemoglobin
<10.0 1.68 (1.31, 2.17) 2.98 (2.05, 4.32)
10.0 to 11.9 1.71 (1.53, 1.91) 2.53 (2.08, 3.07)
12.0+ 1.00 <0.001 1.00 <0.001
Glomerular filtration rate
<30.0 4.58 (3.69, 5.69) 9.50 (6.89, 13.10)
30.0 to 59.9 2.25 (2.04, 2.49) 2.56 (2.10, 3.13)
60.0 to 89.9 1.00 1.00
90.0+ 0.82 (0.72, 0.95) <0.001 0.43 (0.30, 0.62) <0.001
Critical preoperative event
No
Yes 3.35 (2.35, 4.78) <0.001
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Table 10 Model coefficients for final models (complete case data) (Continued)
Catheter to surgery
Within 24 h 1.22 (0.91, 1.64) 1.58 (1.03, 2.43)
>24 hrs this admission 0.78 (0.71, 0.86) 0.71 (0.59, 0.85)
>24 hrs previous admission 1.00 <0.001 1.00 <0.001
Triple vessel disease
No 1.00
Yes 1.22 (1.10, 1.34) <0.001
Ejection fraction
Good (50+ %) 1.00
Fair (30-49%) 1.24 (1.14, 1.36)
Poor (<30%) 1.42 (1.20, 1.67) <0.001
Operative priority
Elective 1.00
Urgent 1.43 (1.30, 1.58)
Emergency/salvage 2.45 (1.74, 3.43) <0.001
Cardiac procedures
CABG only 1.00 1.00
Valve only 1.43 (1.24, 1.65) 1.50 (1.17, 1.92)
CABG+valve 1.89 (1.67, 2.15) 2.15 (1.72, 2.70)
Other/multiple 1.82 (1.57, 2.11) <0.001 2.92 (2.30, 3.72) <0.001
Constant 0.05 (0.04, 0.06) <0.001 0.01 (0.01, 0.02) <0.001
Models are the initial models (variables P <0.001 in models adjusting for main effects). AKI, acute kidney injury; NYHA, New York Heart Association; CABG,
coronary artery bypass graft; Haemoglobin, g/dL; GFR, mL/min.
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non-UK populations. We used well-defined variables that
are routinely collected in UK databases, however, differ-
ences in variable definitions that occur between databases
and countries may limit the wider utility of the model. This
was a limitation of the two North American comparison
scores. The Mehta score, in particular was not composed of
variables that were routinely collected in the UK data,
including MI <3 weeks, and ethnicity. The Mehta score
was also developed in a selected population and both
American scores excluded patients undergoing surgery
without CPB, but were subsequently tested in a UK
population that included a significant proportion of
off-pump procedures. Conversely variable definitions
were largely comparable between the UK and Australian
cohorts, and the Ng score demonstrated good dis-
crimination but poor calibration. This may reflect the
non-consensus definition of AKI used in the Ng score
or differences in patient populations and clinical practice
between the two countries. These findings highlight
the problems of risks scores developed in distinct
geographic populations. The UK AKI risk scores described
here may suffer from similar limitations, and we con-
clude that their wider utility requires independent
external validation.Conclusion
This study has used a large multicentre cohort to develop
and validate a risk prediction score for AKI stages 1 to 3.
This is the only published score that predicts less severe
AKI, as currently defined by the consensus KDIGO
definition. We suggest that this new score core will
have clinical utility for risk stratification and facilitate
cohort enrichment for clinical trials of novel renoprotective
interventions.
Key messages
 AKI is a common and severe complication of
cardiac surgery that contributes to morbidity,
mortality and increased healthcare costs
 Previous trials of renoprotective interventions
have been limited by the enrolment of low- or
mixed-risk AKI cohorts, and no effective treatment
has been identified thus far
 AKI risk scores are an objective and
transparent way of identifying cohorts of
patients at increased risk of AKI for clinical
trials; however, existing scores identify only
those patients who develop severe AKI requiring
renal replacement therapy
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centres to develop a risk score that identifies all
patients at risk of AKI (stages 1 to 3) with high
discrimination and good calibration in an external
validation dataset from a third centre
 The utility of this score is currently being
prospectively validated as a cohort enrichment toll
in several ongoing clinical trials
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